New hope for kidney stone sufferers: Longer-Acting drugs may offer better prevention
NCT ID NCT06111885
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two long-acting drugs, indapamide and chlorthalidone, to the standard short-acting drug hydrochlorothiazide for preventing calcium kidney stones. About 99 adults who have had at least two kidney stones in the past 10 years will participate. The goal is to see if the longer-acting drugs reduce stone-forming substances in urine more effectively.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY STONE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Inselspital, Department of Nephrology and Hypertension
RECRUITINGBern, 3010, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new standard for pain pills after kidney stone surgery?
- Can watching and waiting beat surgery for silent kidney stones?
- New flexible suction sheath may improve kidney stone removal in children
- Could your diet trigger kidney stones by changing your immune system?
- Opioid-Free anesthesia for kidney stone surgery shows promise in new trial
- Spinach smoothie study reveals immune cell energy secrets